US 12,227,568 B2
Anti-Siglec-7 antibodies and methods of use thereof
Patricia Culp, Oakland, CA (US); Seung-Joo Lee, Benicia, CA (US); Helen Lam, Union City, CA (US); Wei-Hsien Ho, Belmont, CA (US); and Arnon Rosenthal, Woodside, CA (US)
Assigned to ALECTOR LLC, South San Francisco, CA (US)
Appl. No. 16/972,840
Filed by Alector LLC, South San Francisco, CA (US)
PCT Filed Jun. 7, 2019, PCT No. PCT/US2019/035990
§ 371(c)(1), (2) Date Dec. 7, 2020,
PCT Pub. No. WO2019/236965, PCT Pub. Date Dec. 12, 2019.
Claims priority of provisional application 62/682,439, filed on Jun. 8, 2018.
Prior Publication US 2021/0246204 A1, Aug. 12, 2021
Int. Cl. C07K 16/00 (2006.01); C07K 16/28 (2006.01); C12P 21/08 (2006.01); C07K 1/00 (2006.01)
CPC C07K 16/2803 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01)] 38 Claims
 
1. An antibody that binds to a Siglec-7 protein, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an HVR-H1, an HVR-H2, and an HVR-H3, and the light chain variable region comprises an HVR-L1, an HVR-L2, and an HVR-L3, wherein:
(a) the HVR-H1 comprises the amino acid sequence GYAFTMAWMN (SEQ ID NO: 2), the HVR-H2 comprises the amino acid sequence RIFPGYGHTN (SEQ ID NO: 8), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDINTYLN (SEQ ID NO: 11), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNLLPWT (SEQ ID NO: 17);
(b) the HVR-H1 comprises the amino acid sequence GYAFTGYWMN (SEQ ID NO: 3), the HVR-H2 comprises the amino acid sequence RIFPGLGHTN (SEQ ID NO: 7), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDTNTYLN (SEQ ID NO: 12), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNTLPWT (SEQ ID NO: 20);
(c) the HVR-H1 comprises the amino acid sequence GYAFTGYWMN (SEQ ID NO: 3), the HVR-H2 comprises the amino acid sequence RIFPGLGHTN (SEQ ID NO: 7), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDINTYLN (SEQ ID NO: 11), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNILPWT (SEQ ID NO: 23); or
(d) the HVR-H1 comprises the amino acid sequence GYAFTAAWMN (SEQ ID NO: 4), the HVR-H2 comprises the amino acid sequence RIFPGLGHTN (SEQ ID NO: 7), the HVR-H3 comprises the amino acid sequence DYSDYYFDY (SEQ ID NO: 10), the HVR-L1 comprises the amino acid sequence RGSQDINTYLN (SEQ ID NO: 11), the HVR-L2 comprises the amino acid sequence YTSRLHS (SEQ ID NO: 16), and the HVR-L3 comprises the amino acid sequence QQGNILPWT (SEQ ID NO: 23).